Prostate Cancer Clinical Trial

The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

Summary

To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Prostate cancer patients scheduled for treatment with Radium-223.

Exclusion Criteria:

Patients not completing their treatment regimen for any reason

Study is for people with:

Prostate Cancer

Estimated Enrollment:

21

Study ID:

NCT03368989

Recruitment Status:

Completed

Sponsor:

The University of Texas Health Science Center, Houston

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

The University of Texas Health Science Center at Houston
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

21

Study ID:

NCT03368989

Recruitment Status:

Completed

Sponsor:


The University of Texas Health Science Center, Houston

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider